Real-world SEER-Medicare data analysis of the evolution of tumor characteristics, first-line therapies and overall survival (OS) in patients with neuroendocrine tumors (NETs)

#3620

Introduction: Recent data on NET therapy utilization and impact in real-world practice are scarce.

Aim(s): Explore evolution of NET characteristics, first-line therapies, and OS from 2000–16.

Materials and methods: Patients ≥65 years with NET diagnosis who received first-line therapy from Jan 2000–Dec 2016 were identified from the SEER-Medicare database. First-line therapies (≥2 prescriptions for ≥3 months [M]) were somatostatin analogues (SSA), chemotherapy (CM), targeted therapy (TT) and combinations, reported for 2000–11 and 2012–16 by therapy initiation. Kaplan-Meier estimators assessed OS (M from diagnosis–death/last therapy information) for the overall period. NET grade was classified by the SEER grading system (defined by histological differentiation).

Conference:

Presenting Author:

Authors: Schneider M, Sinha A, Dasari A, Chan J, Stoffels A,

Keywords: neuroendocrine tumor, NET characteristics, first-line therapy, treatment evolution, treatment patterns, overall survival,